한글목차

미국과 독일의 2025년 FXS 시장 규모는 2,870만 달러, 2030년에는 1억 1,190만 달러에 달할 것으로 예상되며, 2020-2030년 14.7%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.

두 개의 파이프라인 의약품의 도입이 FXS 시장의 주요 성장 촉진요인입니다. Harmony Biosciences의 Zygel과 Shionogi의 zatolmilast입니다. 고가의 파이프라인 의약품인 Zygel과 zatolmilast의 매출은 가장 영향력 있는 성장 촉진요인입니다.

미국과 독일의 취약성 X 증후군(FXS) 시장에 대해 조사 분석했으며, 현재의 치료 옵션, 미충족 수요와 기회, 연구개발 전략, 시장 전망 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 질환 개요

• 취약 X 증후군(FXS) 개요
• 취약 X 증후군(FXS)의 SWOT 분석
• 취약 X 증후군(FXS)의 진행
• 취약 X 증후군(FXS) 진단과 분류

제4장 역학

• FXS로 진단 받은 환자 수, 남성과 여성(2020년-30년)
• FXS로 진단 받은 환자 수 : 성별(2020년)
• 정보원과 조사 방법 : FXS로 진단 받은 환자 수, 남성과 여성(2020년)

제5장 현재의 치료 옵션

• 치료 패러다임
• 현재의 치료 옵션
• 현재의 치료 옵션 : KOL의 견해
• 제품 개요 : SSRI(fluoxetine, sertraline, citalopram, escitalopram)
• 제품 개요 : 기타 항우울제(venlafaxine, bupropion, trazadone)
• 제품 개요 : 정신 자극제(methylphenidate hydrochloride)
• 제품 개요 : 비정형항 정신병약(aripiprazole, risperidone)
• 제품 개요 : 항경련제(lamotrigine, carbamazepine, sodium valproate)
• 제품 개요 : 강압 항불안제(clonidine, guanfacine)
• 제품 개요 : 벤조디아제핀(clonazepam, diazepam)
• 제품 개요 : 리튬(lithium carbonate)
• 미국과 독일의 취약 X 증후군(FXS) 환자수(2025년)

제6장 미충족 요구와 기회

• 취약 X 증후군(FXS)의 미충족 요구
• 질환의 근본적인 병인을 표적으로 하는 치료법
• 행동 대증요법의 유효성과 안전성 프로파일이 개량
• 조기 개입을 위한 조기진단 능력

제7장 연구개발 전략

• 취약 X 증후군(FXS) 임상시험 디자인 동향
• 취약 X 증후군(FXS) 거래 동향

제8장 파이프라인 평가

• 취약 X 증후군(FXS) 파이프라인 개요
• 취약 X 증후군(FXS)에 대한 후기 파이프라인 의약품
• 제품 개요 : Harmony Biosciences Zygel(cannabidiol)
• 제품 개요 : Shionogi zatolmilast
• 제품 개요 : Anavex Life Sciences의 blarcamesine hydrochloride
• 취약 X 증후군(FXS) : 임상시험(단계 II/III) 개요

제9장 시장 전망

• 취약 X 증후군(FXS) 시장 예측
• 시장 성장 촉진요인과 장벽

제10장 부록

제11장 문의

영문목차

This report covers the US and Germany and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030.

The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030.

The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry, these products will be Harmony Biosciences' Zygel and Shionogi's zatolmilast. The sales of high-priced pipeline agents Zygel and zatolmilast represent the most impactful drivers of growth.

Scope

• Overview of Fragile X Sundrome (FXS), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized FXS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the FXS market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for FXS. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the US and German FXS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the US and German FXS therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FXS therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Fragile X Syndrome
• 3.2. Fragile X Syndrome SWOT Analysis
• 3.3. Progression of Fragile X Syndrome
• 3.4. Diagnosis and Classification of Fragile X Syndrome

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of FXS, Men and Women, 2020-30
• 4.2. Diagnosed Prevalent Cases of FXS by Sex, 2020
• 4.3. Sources and Methodology: Diagnosed Prevalent Cases of FXS, Men and Women, 2020

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Current Treatment Options: KOL Perspective
• 5.4. Product Profile: SSRIs (fluoxetine, sertraline, citalopram, escitalopram)
• 5.5. Product Profile: Other Antidepressants (venlafaxine, bupropion, trazadone)
• 5.6. Product Profile: Psychostimulants (methylphenidate hydrochloride)
• 5.7. Product Profile: Atypical Antipsychotics (aripiprazole, risperidone)
• 5.8. Product Profile: Anticonvulsants (lamotrigine, carbamazepine, sodium valproate)
• 5.9. Product Profile: Antihypertensive Anxiolytics (clonidine, guanfacine)
• 5.10. Product Profile: Benzodiazepines (clonazepam, diazepam)
• 5.11. Product Profile: Lithium (lithium carbonate)
• 5.12. Fragile X Syndrome Cases in 2025 in the US and Germany

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Fragile X Syndrome
• 6.2. Therapies that target the underlying etiology of the disease
• 6.3. Improved efficacy and safety profile of behavioral symptomatic treatments
• 6.4. Early diagnosis capability for early intervention

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in Fragile X Syndrome
• 7.2. Trends in Deal-Making in Fragile X Syndrome

8. Pipeline Assessment

• 8.1. Fragile X Syndrome Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Fragile X Syndrome
• 8.3. Product Profile: Harmony Biosciences' Zygel (cannabidiol)
• 8.4. Product Profile: Shionogi's zatolmilast
• 8.5. Product Profile: Anavex Life Sciences' blarcamesine hydrochloride
• 8.6. Fragile X Syndrome: Clinical Trials (Phase II/III) Overview

9. Market Outlook

• 9.1. Fragile X Syndrome Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: KOL Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us